IL-33, sST2, and CRP in Panic Disorder

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorElazığ Mental Health and Diseases Hospital

About this trial

Panic disorder (PD) is characterized by recurrent and unexpected panic attacks and is associated with significant functional impairment. Increasing evidence suggests involvement of immune-inflammatory mechanisms in PD. Elevated levels of inflammatory markers such as C-reactive protein (CRP) have been reported in PD; however, interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), components of the IL-33/sST2 signaling axis, have not previously been investigated in PD. This cross-sectional case-control study aims to compare peripheral serum IL-33, sST2, and CRP levels between drug-naïve subjects diagnosed with PD and healthy controls (HCs). The findings may contribute to understanding the inflammatory mechanisms underlying PD.

Eligibility criteria

Qualifiers

Being between 18-65 years of age

Having a diagnosis of panic disorder (PD) according to DSM-5-TR and having presented to the hospital with panic attack symptoms of the disorder

Not having previously used any medication for psychiatric purposes (drug-naive)

Not having any additional active psychiatric disorders besides PD at the current presentation

Disqualifiers

Taking any medication or supplement in the last month

Incomplete completion of sociodemographic and scale data

Not volunteering to participate in the study

Being between 18-65 years of age

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

80 Participants
are grouped into 2 trial groups